Skip navigation

Dr David Tetard

Assistant Professor

Department: Applied Sciences

I am an organic chemist who is designing novel powerful metal chelators, with a focus on Fe(III) that can have therapeutic applications, in particular against cancer, neurodegenerative diseases (Parkinson's Disease, Alzheimer's Disease) and as biostatic agents against micro-organisms. My molecules are based on rationale design, trying to optimise metal chelator and other functions such as cell penetration, multiple mode of action, targeting.

David Tetard

Metal chelators as therapeutic compounds, in particular in cancer, neurodegenerative diseases and as biostatic agents against microorganisms.

We focus on the design of powerful Fe(III) chelators of the hydroxypyridinone family that have been demonstrated by us and others to have activity as:

anticancer drugs, interfering with the biochemical processes involving metals (metalloenzymes, oxidative stress)

drugs against neurodegenerative diseases, preventing oxidative damage to neurons

biostatic agents, reducing the rate of growth of microorganisms.

  • Please visit the Pure Research Information Portal for further information
  • Novel Iron Chelator SK4 Drives Cytotoxicity through Inhibiting Mitochondrial Metabolism in Ovarian and Triple Negative Breast Cancer Cell Lines, Abdelaal, G., Carter, A., Cheung, W., Panayiotidis, M., Racey, S., Tétard, D., Veuger, S. 24 Jul 2023, In: Biomedicines
  • 1-Hydroxy-2(1H)-pyridinone-Based Chelators with Potential Catechol O-Methyl Transferase Inhibition and Neurorescue Dual Action against Parkinson’s Disease, Bergin, J., Tan, K., Nelson, A., Amarandei, C., Hubscher-Bruder, V., Brandel, J., Voinarovska, V., Dejaegere, A., Stote, R., Tetard, D. 28 Apr 2022, In: Molecules
  • Novel iron chelator SK4 demonstrates cytotoxicity in a range of tumour derived cell lines, Abdelaal, G., Carter, A., Panagiotidis, M., Tetard, D., Veuger, S. 23 Sep 2022, In: Frontiers in Molecular Biosciences
  • Synthesis, physicochemical characterization and neuroprotective evaluation of novel 1-hydroxypyrazin-2(1H)-one iron chelators in an in vitro cell model of Parkinson's disease, Lewis, F., Bird, K., Navarro, J., El Fallah, R., Brandel, J., Hubscher-Bruder, V., Tsatsanis, A., Duce, J., Tetard, D., Bourne, S., Maina, M., Pienaar, I. 1 Mar 2022, In: Dalton Transactions
  • A novel methylated analogue of L-Mimosine exerts its therapeutic potency through ROS production and ceramide-induced apoptosis in malignant melanoma, Kyriakou, S., Cheung, W., Mantso, T., Mitsiogianni, M., Anestopoulos, I., Veuger, S., Trafalis, D., Franco, R., Pappa, A., Tetard, D., Panayiotidis, M. 1 Aug 2021, In: Investigational New Drugs
  • Anticancer activity of a novel methylated analogue of L-mimosine against an in vitro model of human malignant melanoma, Kyriakou, S., Mitsiogianni, M., Mantso, T., Cheung, W., Todryk, S., Veuger, S., Pappa, A., Tetard, D., Panagiotidis, M. 1 Jun 2020, In: Investigational New Drugs
  • Design and evaluation of bi-functional iron chelators for protection of dopaminergic neurons from toxicants, Gutbier, S., Kyriakou, S., Schildknecht, S., Ückert, A., Brüll, M., Lewis, F., Dickens, D., Pearson, L., Elson, J., Michel, S., Hubscher-Bruder, V., Brandel, J., Tetard, D., Leist, M., Pienaar, I. 1 Sep 2020, In: Archives of Toxicology
  • Novel 1‑hydroxypyridin‑2‑one metal chelators prevent and rescue ubiquitin proteasomal‑related neuronal injury in an in vitro model of Parkinson’s disease, Lewis, F., Farooz, S., Elson, J., Hubscher-Bruder, V., Brandel, J., Soundararajan, M., Smith, D., Dexter, D., Tetard, D., Pienaar, I. 1 Mar 2020, In: Archives of Toxicology
  • The influence of linkages between 1-Hydroxy-2(1H)-pyridinone Coordinating Groups and a Tris(2-aminoethyl)amine core in a novel series of synthetic Hexadentate Iron(III) Chelators on antimicrobial activity, Workman, D., Hunter, M., Wang, S., Brandel, J., Hubscher, V., Dover, L., Tetard, D. 1 Jan 2020, In: Bioorganic Chemistry
  • An Overview of Multifunctional Metal Chelators as Potential Treatments for Neurodegenerative Diseases, Lewis, F., Tetard, D. May 2017, Biometals in Neurodegenerative Diseases: Mechanisms and Therapeutics, San Diego, Elsevier

  • Sotiris Kyriakou Synthesis and Biological Evaluation of Metal Chelators of the Hydroxypyridinone Family as Potential Treatment of Parkinson’s Disease and Cancer Start Date: 01/10/2016 End Date: 04/03/2020
  • Maryam Mousadoust Synthesis of Novel Ligands Based on Hydroxypyridinones and Hydroxypyranones and their Corresponding Iron (II) / Iron (III) Complexes Start Date: 15/12/2009 End Date: 12/06/2014
  • David Workman Synthesis of High Affinity Iron(III) Chelators for Use as Biostatic Agents Start Date: 01/09/2010 End Date: 27/03/2014
  • Adam Robinson-Miller Study of Mn(II)/Mn(III) Oxidation Catalysts in Alkene Epoxidation and Chromophore Bleaching Start Date: 01/09/2010 End Date: 20/02/2014
  • Darren Gardner Design, synthesis and evaluation of novel siderophore- chromogen conjugates as diagnostic substrates for the detection of antimicrobial resistant pathogens. Start Date: 01/10/2023

  • Teaching & Learning PCAPL October 10 2008
  • Chemistry PhD October 30 1996
  • Fellow (FHEA) Higher Education Academy (HEA) 2013
  • Member (MRSC) Royal Society of Chemistry (RSC) 1998


a sign in front of a crowd
+

Northumbria Open Days

Open Days are a great way for you to get a feel of the University, the city of Newcastle upon Tyne and the course(s) you are interested in.

Research at Northumbria
+

Research at Northumbria

Research is the life blood of a University and at Northumbria University we pride ourselves on research that makes a difference; research that has application and affects people's lives.

NU World
+

Explore NU World

Find out what life here is all about. From studying to socialising, term time to downtime, we’ve got it covered.


Latest News and Features

Jing Jiang and Eamon Scullion, pictured holding cube sats
Remembering Professor Keith Shaw
Sleeping woman next to a clock
Enterprise Team Northumbria Unviersity
Turing Scheme - Ami Gardiner
Professor Peter Lloyd-Sherlock
More news

Back to top